Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Home

Showing results (181-190 of 231) with videos related to

Pageof 24
Sort By:
Diabetes, Obesity & Metabolism|February 3, 2015
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)G B Bolli, M C Riddle, R M Bergenstal, et al.
Diabetes Care|June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes Research (Edinburgh, Scotland)|November 1, 1984
The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetesB Capaldo, P D Home, M Massi-Benedetti, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0David R Owens, Wolfgang Landgraf, Brian M Frier, et al.
Diabetologia|September 1, 1982
The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas)R Nosadini, G A Noy, M Nattrass, et al.
Diabetes, Obesity & Metabolism|April 8, 2015
One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extensionM C Riddle, H Yki-Järvinen, G B Bolli, et al.
Diabetes Research (Edinburgh, Scotland)|September 1, 1985
A prospective study of the immunogenicity of porcine insulin in HLA-typed new insulin-treated diabeticsL O Almér, G Ekberg, S Fankhauser, et al.
Diabetes, Obesity & Metabolism|August 17, 2021
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparisonPhilip D Home, Roopa Mehta, Khadija A S Hafidh, et al.
Diabetes, Obesity & Metabolism|October 30, 2022
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristicsPhilip D Home, Rory J McCrimmon, Julio Rosenstock, et al.
Diabetologia|March 1, 1982
Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusionJ C Pickup, G C Viberti, R W Bilous, et al.
Pageof 24

Showing results (181-190 of 231) with videos related to

Sort By:
Pageof 24
Diabetes, Obesity & Metabolism|February 3, 2015
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)G B Bolli, M C Riddle, R M Bergenstal, et al.
Diabetes Care|June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes Research (Edinburgh, Scotland)|November 1, 1984
The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetesB Capaldo, P D Home, M Massi-Benedetti, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0David R Owens, Wolfgang Landgraf, Brian M Frier, et al.
Diabetologia|September 1, 1982
The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas)R Nosadini, G A Noy, M Nattrass, et al.
Diabetes, Obesity & Metabolism|April 8, 2015
One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extensionM C Riddle, H Yki-Järvinen, G B Bolli, et al.
Diabetes Research (Edinburgh, Scotland)|September 1, 1985
A prospective study of the immunogenicity of porcine insulin in HLA-typed new insulin-treated diabeticsL O Almér, G Ekberg, S Fankhauser, et al.
Diabetes, Obesity & Metabolism|August 17, 2021
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparisonPhilip D Home, Roopa Mehta, Khadija A S Hafidh, et al.
Diabetes, Obesity & Metabolism|October 30, 2022
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristicsPhilip D Home, Rory J McCrimmon, Julio Rosenstock, et al.
Diabetologia|March 1, 1982
Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusionJ C Pickup, G C Viberti, R W Bilous, et al.
Pageof 24